Phaseline

Targets › FE

FE: drug programs, companies and trials

1 program from 1 company in 2 trials: 2 Phase 3; Hematology; next expected readout Mar 2027.

Open in Phaseline: the race on FE, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
George Washington UniversityMultiple Micronutrient Supplements with 45 mg of elemental iron
Iron supplementation (45 mg elemental iron) with 14 additional micronutrients (UNIMMAP for
FEPhase 3Pregnancy RelatedMar 2027

Conditions

Pregnancy Related (2)

Modalities

–

Companies

George Washington University (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.